155 related articles for article (PubMed ID: 3900906)
1. Double-blind clinical trial of calf lung surfactant extract for the prevention of hyaline membrane disease in extremely premature infants.
Kwong MS; Egan EA; Notter RH; Shapiro DL
Pediatrics; 1985 Oct; 76(4):585-92. PubMed ID: 3900906
[TBL] [Abstract][Full Text] [Related]
2. Double-blind, randomized trial of a calf lung surfactant extract administered at birth to very premature infants for prevention of respiratory distress syndrome.
Shapiro DL; Notter RH; Morin FC; Deluga KS; Golub LM; Sinkin RA; Weiss KI; Cox C
Pediatrics; 1985 Oct; 76(4):593-9. PubMed ID: 3900907
[TBL] [Abstract][Full Text] [Related]
3. Reduced incidence of hyaline membrane disease in extremely premature infants following delay of delivery in mother with preterm labor: use of ritodrine and betamethasone.
Kwong MS; Egan EA
Pediatrics; 1986 Nov; 78(5):767-74. PubMed ID: 3532016
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of exogenous surfactant for the treatment of hyaline membrane disease.
Gitlin JD; Soll RF; Parad RB; Horbar JD; Feldman HA; Lucey JF; Taeusch HW
Pediatrics; 1987 Jan; 79(1):31-7. PubMed ID: 3540835
[TBL] [Abstract][Full Text] [Related]
5. Very early surfactant without mandatory ventilation in premature infants treated with early continuous positive airway pressure: a randomized, controlled trial.
Rojas MA; Lozano JM; Rojas MX; Laughon M; Bose CL; Rondon MA; Charry L; Bastidas JA; Perez LA; Rojas C; Ovalle O; Celis LA; Garcia-Harker J; Jaramillo ML;
Pediatrics; 2009 Jan; 123(1):137-42. PubMed ID: 19117872
[TBL] [Abstract][Full Text] [Related]
6. Prevention of neonatal respiratory distress syndrome by tracheal instillation of surfactant: a randomized clinical trial.
Enhorning G; Shennan A; Possmayer F; Dunn M; Chen CP; Milligan J
Pediatrics; 1985 Aug; 76(2):145-53. PubMed ID: 3895150
[TBL] [Abstract][Full Text] [Related]
7. Surfactant replacement therapy at birth: final analysis of a clinical trial and comparisons with similar trials.
Kendig JW; Notter RH; Cox C; Aschner JL; Benn S; Bernstein RM; Hendricks-Munoz K; Maniscalco WM; Metlay LA; Phelps DL
Pediatrics; 1988 Nov; 82(5):756-62. PubMed ID: 3054783
[TBL] [Abstract][Full Text] [Related]
8. Bovine surfactant (surfactant TA) therapy in immature baboons with hyaline membrane disease.
Vidyasagar D; Maeta H; Raju TN; John E; Bhat R; Go M; Dahiya U; Roberson Y; Yamin A; Narula A
Pediatrics; 1985 Jun; 75(6):1132-42. PubMed ID: 3846883
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of severe hyaline membrane disease with a single-dose of natural exogenous surfactant of porcine origin. A randomized trial: immediate effects and outcome at 28 days of life].
Walti H; Relier JP; Huon C; Monset-Couchard M; Scemama M; De Gamarra E; Moriette G; Curstedt T; Robertson B
Arch Fr Pediatr; 1990 May; 47(5):329-34. PubMed ID: 2196030
[TBL] [Abstract][Full Text] [Related]
10. The antenatal use of ambroxol (bromhexine metabolite VIII) to prevent hyaline membrane disease: a controlled double-blind study.
Wauer RR; Schmalisch G; Menzel K; Schröder M; Müller K; Tiller R; Methfessel G; Sitka U; Koepke E; Plath C; Schlegel C; Böttcher M; Köppe I; Fricke U; Severin K; Jacobi R; Schmidt W; Hinkel GK; Nitz I; Kunze D; Reichmann G; Lachmann B; Lampe K; Grauel EL
Int J Biol Res Pregnancy; 1982; 3(2):84-91. PubMed ID: 7042592
[TBL] [Abstract][Full Text] [Related]
11. Delivery room continuous positive airway pressure/positive end-expiratory pressure in extremely low birth weight infants: a feasibility trial.
Finer NN; Carlo WA; Duara S; Fanaroff AA; Donovan EF; Wright LL; Kandefer S; Poole WK;
Pediatrics; 2004 Sep; 114(3):651-7. PubMed ID: 15342835
[TBL] [Abstract][Full Text] [Related]
12. Repeat surfactant therapy for postsurfactant slump.
Katz LA; Klein JM
J Perinatol; 2006 Jul; 26(7):414-22. PubMed ID: 16724122
[TBL] [Abstract][Full Text] [Related]
13. Decreased respiratory compliance in infants less than or equal to 32 weeks' gestation, delivered more than 7 days after antenatal steroid therapy.
McEvoy C; Schilling D; Spitale P; Peters D; O'Malley J; Durand M
Pediatrics; 2008 May; 121(5):e1032-8. PubMed ID: 18450845
[TBL] [Abstract][Full Text] [Related]
14. The effects of surfactant and antenatal corticosteroid treatment on the pulmonary pathology of preterm infants with respiratory distress syndrome.
Teksam O; Kale G
Pathol Res Pract; 2009; 205(1):35-41. PubMed ID: 18951732
[TBL] [Abstract][Full Text] [Related]
15. Gestational age can predict the need for prophylaxis with surfactant therapy.
Mbuyamba M; Holman M; Kresch MJ
Am J Perinatol; 1998 Apr; 15(4):263-7. PubMed ID: 9565226
[TBL] [Abstract][Full Text] [Related]
16. [The therapeutic use of pulmonary surfactant in neonatal hyaline membrane disease].
Lozano-González CH; Piña-Ceballos VM; Beyer-Obezo J; Gutiérrez-Martín A; Martínez-Hinojosa B; Flores-Támez ME
Bol Med Hosp Infant Mex; 1993 Jul; 50(7):481-91. PubMed ID: 8363747
[TBL] [Abstract][Full Text] [Related]
17. Hyaline membrane disease. Effect of surfactant prophylaxis on lung morphology in premature primates.
Cutz E; Enhörning G; Robertson B; Sherwood WG; Hill DE
Am J Pathol; 1978 Sep; 92(3):581-94. PubMed ID: 99046
[TBL] [Abstract][Full Text] [Related]
18. Comparison outcomes of surfactant therapy in respiratory distress syndrome in two periods.
Chotigeat U; Promwong N; Kanjanapattanakul W; Khorana M; Sangtawesin V; Horpaopan S
J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S109-14. PubMed ID: 19253505
[TBL] [Abstract][Full Text] [Related]
19. Surfactant treatment may accelerate epithelial cell regeneration in hyaline membrane disease of the newborn.
Gonda TA; Hutchins GM
Am J Perinatol; 1998; 15(9):539-44. PubMed ID: 9890252
[TBL] [Abstract][Full Text] [Related]
20. Endotracheal continuous positive airway pressure after rescue surfactant therapy.
Mandy GT; Moïse AA; Smith EO; Hansen TN
J Perinatol; 1998; 18(6 Pt 1):444-8. PubMed ID: 9848758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
